Insights into RNA Interference as Antiviral Defense

Purushottam Narute*
Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD, USA

Abstract

The beginning of this century is marked by discovery of “RNA interference (RNAi)” and led to Nobel Prize award in Physiology or Medicine jointly to Andrew Z Fire and Craig C Mello in 2006. Initially discovered as innate antiviral defense mechanism in plants it has great implications as therapeutic tools to combat with animal and human viruses as well as research tool to study disease pathogenesis. This article reviews the mechanism of RNAi and outlines recent research directed toward development as antiviral defense in human and animal diseases.

Keywords: Antiviral; HCV; HIV-1; RNAi; miRNA; siRNA; siRNA delivery

Introduction

RNAi or double stranded RNA (dsRNA) dependent post-transcriptional gene silencing is evolutionarily conserved cellular mechanism thought to be evolved as defence mechanism to protect the organisms against viral infections. Fire and Mello discovered that introduction of dsRNA resulted in profound specific gene silencing in adult animals and this effect is vertically transferable into progeny [1]. This phenomenon occurs in wide variety of eukaryotic organisms by generating small 21-25 nt single stranded RNA (ssRNA) from exogenously introduced dsRNA or endogenous RNA through series of processing by nucleases and cellular proteins, which leads to sequence-specific binding to messenger RNA (mRNA) and its silencing [2]. There are several noncoding RNAs described in eukaryotic organisms including microRNA (miRNA), small nuclear RNAs (snRNAs), small nucleolar RNAs (snoRNAs), long noncoding RNAs (lncRNAs) and small interfering RNA (siRNA) [3,4]. The phenomenon of RNA interference is widely accepted as antiviral defense as well as molecular probes to investigate the viral pathogenesis. This article discusses the mechanism of RNAi in animal cells by endogenous as well as exogenous dsRNAs and their implication as tool to combat with viruses.

Mechanism of RNA Interference

The major player of RNAi is 21-25 nt ssRNA which binds sequence-specifically to mRNA with help of argonaute-family ribonucleaseprotein complex known as RNA-induced silencing complex (RISC). Depending upon the percent complementary of with target mRNA either this binding leads to degradation or translation repression of target mRNA. This ssRNA is generated from both exogenously delivered dsRNA and endogenous long ~ 1 kilobases RNA transcript known as primary miRNA (pri-miRNA) through similar mechanism [4-7]. In endogenous pathway, the pri-miRNA is cleaved into small 60-70 nt pre-miRNA by microprocessor complex composed of Drosha and DGCR8 [8] Then resulting pre-miRNA is cleaved into small 21-25 nt pre-miRNA by dicer enzyme and processed into 21-25 nt dsRNA [4,10]. With help of argonaute, dsRNA-binding protein (DSRBP) and dicer, this dsRNA forms RNA induced silencing complex (RISC) and one of the strand of dsRNA is degraded. Then argonaute and siRNA direct this complex to target mRNA which leads to silencing of expression of target mRNA [10-12]. This is illustrated in Figure 1.

A wide variety of tools including web-based algorithms and...
software's are available to design of effective siRNA targeting specific genes [13-16]. Then these exogenous siRNA are synthesized by chemical synthesis, in vitro transcription or transfection of plasmid/viral vectors containing siRNA sequences for expression in cells [17-19].

**RNAi in Antivirus Defense**

Since last one decade, several studies have reported use of RNAi to inhibit replication of retroviruses, respiratory syncytial virus, influenza virus, poliovirus, herpes viruses and hepatitis c virus. These studies have used either synthetic siRNA or expressed shRNA delivered via transfection or transduction [20-26]. The synthetic and in vitro transcribed siRNA targeting HIV-1 gag gene, regulatory proteins such as Tat and rev, resulted in strong inhibition of both T- and M-tropic HIV replication [27-31]. Moreover, siRNA targeting essential host cell factors for HIV-1 replication effectively inhibits HIV-1 replication in cell culture [30,32]. Similar to HIV-1, targeting influenza virus essential genes including PB2, M2 and NP resulted in strong inhibition of virus in cell culture [33-35].

In addition to these synthetic exogenous siRNA, the endogenous human miRNAs also play important role in viral pathogenesis. The human mir-332 inhibits West Nile Virus indirectly by suppressing expression of host proteins TAB3 and SEDST1 [36]. Similarly, mir-29 family plays important role in decreasing HIV-1 viral load, progression to AIDS as well as boosting host immunity [37]. Moreover, several miRNAs play important role in HIV-1 pathogenesis either by directly inhibiting viral genes or host cell factors important in viral pathogenesis [38]. Harilaran et al. using target prediction softwares demonstrated that four human mir-29a/b, mir-149, mir-378 and mir-324-5p targets nef, vpr, env and vir genes respectively [39]. The group of human miRNAs including miR-28, miR-125b, miR-150, miR-223 and miR-382 targets 3’ end of HIV-1 mRNAs and significantly decrease HIV-1 replication in resting CD4+ T cells [40]. Similarly, mir-let-7c, mir-192 and mir-142 inhibit influenza virus replication [41-43].

The siRNA even delivered in vivo in infected animals inhibited Japanese encephalitis virus in mice, HBV and influenza virus in transgenic mice [44-46]. The HIV-1 core as well as accessory proteins and several essential host genes used as RNAi target for HIV-1 inhibition in vivo using humanized mice infected with HIV-1. These studies showed significant reduction in viremia and infection associated syndromes in mice as well as resistance to HIV-1 infection in humanized BLT mice [47,48]. The siRNA targeting NS1 gene of influenza strongly inhibited virus replication in mice [49].

**Delivery of Small RNA**

The siRNAs are delivered to cells by transfection of synthetic or plasmid expressing siRNA using cationic liposomes, polyamines as well as electroproportion and viral transduction. This delivery can be enhanced with chemical modification by conjugation with bioactive moieties and nanoparticles [50]. Moreover, negative charge of siRNA enabled the use of cationic peptide such as including poly(l-lysine) (PLL), protamine and cell penetrating peptides (CPP) as a efficient and stable carrier for delivery [51]. Further research demonstrated that gold nanoparticles as efficient vehicles for siRNA delivery in vitro and in vivo as well as enhances stability [52]. Recently, Duan et al. demonstrated efficient delivery of siRNAs to the liver for targeting hepatitis C virus using vitamin E and cholesterol-based cationic liposomes (VE-DC) without toxicity [26].

**Conclusion**

RNA interference is innate, sequence-specific antiviral defense mechanism in plants and lower eukaryotes and this can be potentially used as tool against animal and human viruses. These small single stranded RNA can be designed to target specific gene important for viral replication and pathogenesis. Recent research highlights the discovery of endogenous miRNA inhibiting viral infection. This si/miRNA clears viral infection by directly inhibiting target genes without causing adverse effect on host cells. This beauty of RNAi kindles hope of developing an effective therapeutics against deadly viral diseases.

**References**

1. Fire A, Xu S, Montgomery MK, Costas SA, Driver SE, et al. (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391: 806-811.

2. Meister G, Tuschi T (2004) Mechanisms of gene silencing by double-stranded RNA. Nature 431: 343-349.

3. Morris KV, Mattick JS (2014) The rise of regulatory RNA. Nat Rev Genet 15: 423-437.

4. Wilson RC, Doudna JA (2013) Molecular mechanisms of RNA interference. Annu Rev Biophys 42: 217-239.

5. Hannon GJ (2002) RNA interference. Nature 418: 244-251.

6. Hammond SM, Bernstein E, Beach D, Hannon GJ (2000) An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 404: 293-296.

7. Zamore PD, Tuschi T, Sharp PA, Bartel DP (2000) RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 101: 25-33.

8. Kim YK, Kim VN (2007) Processing of intrinsic microRNAs. EMBO J 26: 775-783.

9. Lund E, Dahlberg JE (2006) Substrate selectivity of exportin 5 and Dicer in the biogenesis of microRNAs. Cold Spring Harb Symp Quant Biol 71: 59-66.

10. Agrawal N, Dasaradhi PV, Mohammed A, Malhotra P, Bhatnagar RK, et al. (2003) RNA interference: biology, mechanism, and applications. Microbiol Mol Biol Rev 67: 657-685.

11. Parco Z, Liu Q, Wang X (2007) Biochemical mechanisms of the RNA-induced silencing complex. Cell Res 17: 187-194.

12. Hammond SM (2005) Dicing and slicing: the core machinery of the RNA interference pathway. FEBS Lett 579: 5822-5829.

13. Reynolds A, Leake D, Boese Q, Scarringe S, Marshall WS, et al. (2004) Rational siRNA design for RNA interference. Nat Biotechnol 22: 326-330.

14. Naito Y, Yamada T, Ui-Tei K, Morishita S, Saigo K (2004) siDirect: highly effective, target-specific siRNA design software for mammalian RNA interference. Nucleic Acids Res 32: 124-129.

15. Wang L, Mu FY (2004) A Web-based design center for vector-based siRNA and siRNA cassette. Bioinformatics 20: 1816-1820.

16. Matveeva O, Nechipurenko Y, Rossi L, Moore B, Saetrom P, et al. (2007) Comparison of approaches for rational siRNA design leading to a new efficient and transparent method. Nucleic Acids Res 35: e63.

17. Amarziguiou M, Rossi JJ, Kim D (2005) Approaches for chemically synthesized siRNA and vector-mediated RNAi. FEBS Lett 579: 5974-5981.

18. Yu JY, DeRuitter SL, Turner DL (2002) RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. Proc Natl Acad Sci U S A 99: 5047-5052.

19. Yang D, Buchholz F, Huang Z, Goga A, Chen CY, et al. (2002) Short RNA duplexes produced by hydrolysis with Escherichia coli RNase III mediate effective RNA interference in mammalian cells. Proc Natl Acad Sci U S A 99: 9942-9947.

20. Herrera-Carrillo E, Berkhout B (2015) The impact of HIV-1 genetic diversity on the efficacy of a combinatorial RNAi-based gene therapy. Gene Ther 22: 485-495.
21. Vasselton T, Bottlier M, Saumet A, Lecellier CH (2013) RNAi and retroviruses: are they in RISC? Biomet Concepts 4: 43-52.

22. Paavilainen H, Lehtinen J, Romanovskaya A, Nygardas M, Bamford DH, et al. (2016) Inhibition of clinical pathogenic herpes simplex virus 1 strains with enzymatically created siRNA pools. J Med Virol.

23. Narute PS, Raut AA, Saini M, Rai A, Gupta PK (2009) Inhibition of Bovine herpesvirus multiplication in MDBK cells by small interfering RNAs. Acta Virol 53: 203-206.

24. Bilko V, Musiyenko A, Shulyayeva O, Barik S (2005) Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 11: 50-55.

25. Gitlin L, JK Stone, R Andino (2005) Poliovirus escape from RNA interference: short interfering RNA-target recognition and implications for therapeutic approaches. J Virol 79: 1027-1035.

26. Duan L, Yan Y, Liu J, Wang B, Li P, et al. (2016) Target delivery of small interfering RNAs with vitamin E-coupled nanoparticles for treating hepatitis C. Sci Rep 6: 24867.

27. Capodici J, Karkikó K, Weissman D (2002) Inhibition of HIV-1 infection by small interfering RNA-mediated RNA interference. J Immunol 169: 5196-5201.

28. Coburn GA, Cullen BR (2002) Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference. J Virol 76: 9225-9231.

29. Lee NS, Dohjima T, Bauer G, Li H, Li MJ, et al. (2002) Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol 20: 500-505.

30. Novina CD, Murray MF, Dykhoom D, Beresford PJ, Riess J, et al. (2002) siRNA-directed inhibition of HIV-1 infection. Nat Med 8: 681-686.

31. Scarborough RJ, Adams KL, Daher A, Galigoni A, et al. (2015) Effective inhibition of HIV-1 production by short hairpin RNAs and small interfering RNAs targeting a highly conserved site in HIV-1 gag RNA is optimized by evaluating alternative length formats. Antimicrob Agents Chemother 59: 5297-5305.

32. Fu GF, Pan JC, Lin N, Hu HY, Tang WM, et al. (2014) siRNA against KIR3DL1 as a potential gene therapeutic agent in controlling HIV-1 infection. Viral Immunol 27: 207-213.

33. Behera P, Nagarajan S, Murugkar HV, Kalaiyarasu S, Prakash A, et al. (2015) siRNAs targeting PB2 and PB genes potentially inhibit replication of Highly Pathogenic H5N1 Avian Influenza Virus. J Biosci 40: 233-240.

34. Sui HY, Zhao GY, Huang JD, Jin DY, Yuen KY, et al. (2009) Small interfering RNA targeting m2 gene induces effective and long-term inhibition of influenza A virus replication. PLoS One 4: e5671.

35. Stoppani E, Bassi I, Dotti S, Lizzier M, Ferrari M, et al. (2015) Expression of a single siRNA against a conserved region of NP gene strongly inhibits in vitro replication of different Influenza A virus strains of avian and swine origin. Antiviral Res 120: 16-22.

36. Slonchak A, Shannon RP, Pali G, Khromykh AA, et al. (2016) Human MicroRNA miR-532-5p Exhibits Antiviral Activity against West Nile Virus via Suppression of Host Genes SESTD1 and TAB3 Required for Virus Replication. J Virol 90: 2388-2402.

37. Monteileone K, Selvaggi C, Cacciotti G, Falasca F, Mezzaroma I, et al. (2015) MicroRNA-29 family expression and its relation to antiviral immune response and viro-immunological markers in HIV-1-infected patients. BMC Infect Dis 15: 51.

38. Swaminathan G, Navas-Martin S, Martin-Garcia J (2014) MicroRNAs and HIV-1 infection: antiviral activities and beyond. J Mol Biol 426: 1178-1197.

39. Harirhan M, Scaria V, Pillai B, Brahmachari SK (2005) Targets for human encoded microRNAs in HIV genes. Biochem Biophys Res Commun 337: 1214-1218.

40. Huang J, Wang F, Arygir E, Chen K, Liang Z, et al. (2007) Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nat Med 13: 1241-1247.

41. Langlois RA, Vardy B, Chua MA, Garcia-Sastre A, tenOever BR (2012) Hematopoietic-specific targeting of influenza A virus reveals replication requirements for induction of antiviral immune responses. Proc Natl Acad Sci U S A 109: 12117-12122.

42. Langlois RA, Albright RA, Kimberly B, Sutton T, Shapiro JS, et al. (2013) MicroRNA-based strategy to mitigate the risk of gain-of-function influenza studies. Nat Biotechnol 31: 844-847.

43. Ma YJ, Yang J, Fan XJ, Zhao HB, Hu W, et al. (2012) Cellular microRNA let-7c inhibits M1 protein expression of the H1N1 influenza A virus in infected human lung epithelial cells. J Cell Mol Med 16: 2539-2546.

44. Shen T, Liu K, Miao D, Cao R, Chen P (2014) Effective inhibition of Japanese encephalitis virus replication by shRNAs targeting viral genes in vitro and in vivo. Virology 454-455: 48-59.

45. Ivacki D, Ely A, Ferry N, Arbuthnot P (2015) Sustained inhibition of hepatitis B virus replication in vivo using RNA-activating lentiviruses. Gene Ther 22: 163-171.

46. Wise TG, Schafer DS, Lowenthal JW, Doran TJ (2008) The use of RNAi and transgenics to develop viral disease resistant livestock. Dev Biol (Basel) 132: 163-171.

47. Swamy MN, Wu H, Shankar P (2016) Recent advances in RNAi-based strategies for therapy and prevention of HIV-1/AIDS. Adv Drug Deliv Rev 103: 174-186.

48. Shimizu S, Ringpis GE, Marsden MD, Cortado RV, Wilhalme HM, et al. (2015) RNAi-Mediated CCR5 Knockdown Provides HIV-1 Resistance to Memory T Cells in Humanized BLT Mice. Mol Ther Nucleic Acids 4: e227.

49. Rajput R, Khanna M, Kumar P, Kumar B, Sharma S, et al. (2012) Small interfering RNA targeting the nonstructural gene 1 transcript inhibits influenza A virus replication in experimental mice. Nucleic Acid Ther 22: 414-422.

50. Roberts TC, Ezazat K, E Andaloussi S, et al. (2016) Synthetic SIRNA Delivery: Progress and Prospects. Methods Mol Biol 1364: 291-310.

51. Shukla RS, Qin B, Cheng K (2014) Peptides used in the delivery of small noncoding RNA. Mol Pharm 11: 3095-3408.

52. Paul AM, Shi Y, Acharya D, Douglas JR, Cooley A, et al. (2014) Delivery of antiviral small interfering RNA with gold nanoparticles inhibits dengue virus infection in vitro. J Gen Virol 95: 1712-1722.